Tuesday, March 25, 2014

Cisco Joins Cloud Computing Industry with $1B Plan

Two weeks ago we took a full position in Cisco Systems Inc. (CSCO) purchasing approximately 275 shares at $21.77.  Cisco has recently released news that they will spend $1 Billion over the next two years to launch the world’s largest global intercloud.  Cisco plans to use the money to build data centers to run their new service Cisco Cloud Services.  Cisco believes that they will disrupt the market by offering unmatched capabilities such as bringing a network of partners within their intercloud, focusing on apps rather than infrastructure, and incorporating real-time analytics.


The market reacted extremely positive to this news as Cisco was up 3.5% today and 4% since the announcement.  This expansion bolsters my belief that Cisco’s diversification into all areas of IP-based networking and its goal of reaching “Internet of Everything” will drive its share price.

Monday, March 24, 2014

Visa in Russia


In the global market, Visa and MasterCard are facing a big threat from China’s UnionPay, which is accepted in 141 countries and was used for $3.3 trillion in purchases in 2012. That was less than the $5.7 trillion that went through Visa-branded cards, but more than MasterCard’s $2.7 trillion.
As the risen issue between the US and Russian. Legislation has already been introduced in Russia’s parliament that would ban the use of payment systems based outside of the country. As Visa and MasterCard cut off services to sanctioned organisations. Last Friday, the payment networks said they could stop servicing the sanctioned Bank Rossiya, along with three more banks connected. It means any Visa and MasterCard issued by sanctioned banks cannot make payment.
Visa Inc. and PULSE, a Discover Financial Services company, announced an agreement to enable financial institutions that issue EMV debit cards on both the Visa and PULSE networks to use Visa’s common debit solution. Visa’s common application identifier (AID) supports U.S. debit regulations requiring the ability to route transactions over multiple, unaffiliated networks. A common debit solution shared among all participants will help to accelerate EMV chip adoption in the United States and provide a uniform platform that will enable network innovation. In addition, as reported in the beginning of the semester, an appeals court upheld a ruling in a case on debit-card swipe fees. Retailers challenged the Fed Cap in a multi-billion fight over transaction costs. The court said the Fed acted within its authority when it capped debit card swipe fees at 21 cents.

Friday, March 21, 2014

Last week we purchased 127 shares of Citigroup (C) at $47.57.  I will write this blog to give an overview of the company and my investment thesis.  

     After the 2008 crisis, Citi lost all it's shareholders trust, leading to a $450+ decline in share price.  They received over $40 Billion TARP bailout dollars from the government which took a 37% stake in the company.  The gov't put restrictions on the company, limiting the CEO salary to $1 and disallowing dividends.  Within two years Citi repaid the feds in full, who in turn sold off their remaining shares. The company followed with a 1-10 reverse stock split, meaning an investor who owned 10 shares of $4 apiece, now owned one share worth $40. 

After the crisis, Citi split it's segments into Citicorp, it's central operations, and Citiholdings which are all the bad assets from the crisis and are looking to sell off,  Citi sold 25% of Citiholdings in 2013, and now sits at only 6% of assets. They are waiting for an economically proper time to sell the rest. 

Much of my investment thesis centered around it's cheap valuation.  They are currently the lowest valued of the largest US banks.  It's forward P/E of 8.6x is a 45% discount to the S&P's. Compared to a banking index, it's P/B of .74 is a 50% discount to the average.  It's P/E and PEG are also at a 24% and 15% discount respectively.  It's at a 25% discount to P/TB, which leads that the stock should be trading at it's tangible book value of $65/share.  They are actually the only major bank trading below their book value.  (BOA 1.6 BV, Wellsfargo 2.2 BV etc)

This discount may be because the market carries a negative sentiment regarding the company since the crisis, leaving it tarnished after a government bailout.  But as the financial crisis fades and the economy moves towards new heights, the stock should elevate in price.   Also, the current CEO Michael Corbat is focused on turning the conglomerate back into a "boring bank" which I translate into a safer bank.  He is focused on cost-cutting and retracting from poorly performing markets with better asset allocation, has been very successful.  

The results of the Fed's stress test came out yesterday, and deemed well for the banking industry overall.  Citi's position is slightly worse.  They declined in Tier 1 common ratio from 8.3% (which led he banks last year) to 7% this year.  This is still above the fed's requirement of 5%, and will most likely bode for an increase in dividends.  

 The week we bought the stock it declined a few dollars, which was the perfect dip in price I was looking for.  After one week, the stock is trading at $50.36 ( 1pm friday) representing a 5.88% increase since we bought in.  My price target is $58. I will keep you guys posted. 

Tuesday, March 11, 2014

Integra LifeSciences Holdings Corporation


Integra LifeSciences Holdings Corporation released Q4 and FY 2013 Earnings Results, February 25, 2014. The fourth quarter ended with an EPS of $.078 and revenue of $220.76M. Integra missed consensus EPS estimates of $0.81 by $0.03 and revenue consensus of $223.38M by $2.6M. Fiscal Year revenues were $836.2M, representing a 0.6% year-over-year increase. Throughout 2013, Integra launched more than 20 new products in the US and filed for over 50 internationally. U.S. extremities were up 16% and global extremities up 13% versus 2012.

Management predicts the highest growth in their U.S. Neurosurgery revenue for 2014 with an increase 30-35%. Their other segments of revenue drivers, including U.S. instruments, U.S. Extremities, U.S. Spine, and international revenues are expected to increase low-single digits to mid-teens by the end of 2014. For the first few months of the fiscal year, Integra will be focused on a smooth integration of their recent acquisition of the DuraSeal product line into their U.S. Neuro and international segments in order to maximize growth potential, sales, and customer service. In addition, they plan to introduce a number of new products, which include an expandable interbody device, and several products to the wrist, foot, and ankle product lines. A main focus of research and development for Integra going forward is the shoulder market.  They just launched the beginning of their shoulder portfolio last month, which includes total, reverse, and Humeral plating solutions.  Integra also recently launched Titanium Bone Wedges, after receiving clearance from the FDA, as an addition to their foot and ankle portfolio.  This product is used in flatfoot correction procedures.

We hold our investment thesis and expect the international sales and new product development to be drivers for Integra in 2014.  Their newly appointed Corporate Vice President and Chief Scientific Officer, Kenneth Burhop is focused on “developing and commercializing exciting new technologies in regenerative medicine.”  Management guidance puts GAAP gross margin between 61-63% and the adjusted gross margin to be between 64-65%, which is a 1.5 point improvement compared to the current year.  Due to the Medical Device Tax, Integra expects future tax rates to increase to 30-31%.  1Q2014 revenue is expected to be in the range of $210-$215M.  We have an updated 12M price target of $53.14, representing an 8.9% upside from the current price of $48.81.

Tuesday, March 4, 2014

Exit 1/3 of Spirit Airlines Position

We plan to exit approximately 1/3 of our Spirit Airlines position as a result of strong upside over the past 6 months, and minimal upside remaining. We believe that now is a good time to start winding down our position. The stock is up approximately 70% since we initiated our position, and cut our initial position of 175 shares to 150 shares in October, and following the recent move from $47 to $60 we are cutting our position again to around 100 shares. We believe that Spirit continues to have strong growth potential, however the recent stock price move has far outpaced growth, and that is the primary driver for exiting a portion of the position. We have a price target of $67 on the remaining shares, representing an additional 11% upside from today's levels.

Friday, February 21, 2014

Masimo 2013 Financial Results

Masimo Corp is global leader in non-invasive patient monitoring technologies. Their major products fall under their SET series, a breakthrough in pulse oximetry that can detect life threatening events and their Rainbow SET series, which is a noninvasive monitoring platform enabling the assessment of multiple blood constituents and physiologic parameters that previously required invasive or complicated procedures. On February 13th, Masimo reported earnings for fourth quarter and year ended December 28th, 2013.

Fourth quarter had an 8% increase in total revenues to $142.4 million with an equal 8% rise in product revenues to $134.7 million. Masimo rainbow revenue rose to 34% to $14.8 million and SET and Rainbow shipments were $42,000.

For 2014, Masimo had an 11% rise in total revenues to $547.2 million and equal 11% rise in product revenues to $517.4 million. Rainbow revenues rose 21% to $14.8 million and combined SET and Rainbow shipments were 42,000.

Despite positive full year results, Q4 revenues missed expectations. Q4 saw net income of $9.3 million compared to $15.0 million in Q4 2012. Net income for the fourth quarter included $4.6 million in charges for inventory write-downs. Masimo also payed out $8 million in various charges related to an arbitration award ruling.

The award ruling led to a $5.4 million payout to two former sales employees who claimed to being forced to sell faulty devices, which consequently created an intolerable work environment. Masimo who insisted on going through an arbitrator will be asking a federal court to overturn the decision.

Masimo’s stock price has seen a 10% dip over the past week. The poor performance in share price can mainly be attributed to soft 4th quarter results. There has also been growing skepticism in Masimo’s recent expansion in India given the late uncertainty in emerging markets.

Management expects revenues in 2014 to fall between $578 and $598 million. As a current global leader in non-invasive patient monitoring technologies Masimo’s target growth in their current products as well as the success within their pipeline will tell the story moving forward.

In Masimo’s earnings call CEO Joe Kiani addressed questions regarding target revenues for the Rainbow sensors. Rainbow revenues for 2013 reached $14.8 million, which are expected to hit $60 million by the end of 2014. Kiani reported this was a conservative estimate in absence of some disaster occurring that should be met with large orders of SpCO expected towards the end of this year.

In 2013, Masimo had their eye on three potential acquisitions in which Kiani has responded that the company still has their eye on two of the candidates. It is important to note that these acquisitions if they take place would be smaller “tuck-in” types, comparable to previous acquisitions such as PHASEIN, SedLine, and Masimo Semiconductor.

In 2014 I expect to see moderate growth in Masimo’s SET and Rainbow devices and a positive response to Masimo’s new CE Marking of O3 regional oximetry for the Root patient monitoring and connectivity platform. The CE Marking O3 for the root enables monitoring of tissue oxygenation saturation and arterial blood oxygenation. Having just been announced in January of this year the O3’s addition to the root could be key in driving sales for that platform. Moving forward I remain with concerns due to Masimo’s expansion into India. In the earnings call CEO Joe Kiani restated his confidence regarding continued growth within the US. However, expansions into emerging markets, which may continue down a path of volatility should raise investor awareness. Currently I have a neutral position on Masimo. It’s recommended to pay close attention quarterly targets for the Rainbow SET devices and new product and pipeline announcements soon to take place this year.

-Jerome O'Grady
Healthcare analyst

Thursday, February 20, 2014

Spirit Airlines Earnings Report

On January 19th, 2014 Spirit Airlines reported their 4th Quarter financial results.  Spirit Airlines beat consensus earnings per share estimates by 6 cents, $.56, and reported $420.0 million in revenue missing consensus by $1.44 million.  Harsh weather was factored in Spirit's stock price as shareholders were expecting revenue to be impacted by the conditions.  Spirit was up 5% yesterday, reaching a new 52 week high of 51.95.  This was due to shareholder's valuing Spirit's growth year over year, operating revenue was up 27.9% year over year, as well as RASM was up 3% to $.1143.  Another strong result was their completion factor increased to 99.5% compared to 98.4 year over year and CASM ex-fuel down 2.5% year over year.

For 2013, Spirit Airlines grew capacity by 22.2% and net income increased 71% to 178 million year over year.  For the year Spirit's CASM ex-fuel was down 1.5% year over year as well as no debt on their balance sheet, with 531 million in unrestricted cash flow.  Spirit Airline's was able to grow significantly with continuing to offer their customers with low ticket prices, but being able to charge customers for any other fee.

Outlook:  In 2014 Spirit Airlines is expecting higher costs that will ramp for growth in 2015.  These higher costs are due to depreciation and amortization.  There are heavy maintenance events and increases in pilot costs that will drive costs higher.  In the first quarter CASM ex-fuel is expected to grow 1 to 2 percent year over year as well as due to Easter being shifted to April it will affect RASM by 1.5 percent.  The fuel price per gallon is also expected to be $3.17 and capacity is expected to increase by 21 percent year over year.  For the year in 2014 there will be 11 new aircraft's, fuel prices per gallon are expected to be $3.12, capacity increase by 17 percent and full year CASM ex-fuel increases by 2%.  In 2015 the higher costs and expenditure on new aircraft from 2014 will drive lower maintenance costs and revenue from new aircraft will be realized.  In 2015 capacity is expected to grow 29% compared to 2014 with an addition of 14 new aircraft.

Spirit Airlines has continued to show that their extremely low ticket prices are attractive to customers and will continue to be in the future, as well as an increase in their completion factor represents efficiency in travel and customer satisfaction.  It will be important to monitor in 2014 how much higher maintenance costs will affect profit, but given that Spirit has no current debt on their balance sheet I believe they will be able to monitor these costs while continuing to increase operating revenue. Spirit Airlines is still expected to grow capacity by 17% year over year and provide customer's with their valuable prices and services.  Capital expenditure in new aircraft is a positive sign that Spirit is looking to continue expanding. Spirit still has upside in 2014, but monitoring weather effects and higher cost's on operating revenue will be crucial.

Industrial Analyst- Guillermo Dilone